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ABSTRACT
Background Responses to immunotherapy vary 
between different cancer types and sites. Here, we 
aimed to investigate features of exhaustion and 
activation in tumor- infiltrating CD8 T cells at both 
the primary and metastatic sites in epithelial ovarian 
cancer.
Methods Tumor tissues and peripheral blood were 
obtained from 65 patients with ovarian cancer. 
From these samples, we isolated tumor- infiltrating 
lymphocytes (TILs) and peripheral blood mononuclear 
cells. These cells were used for immunophenotype 
using multicolor flow cytometry, gene expression profile 
using RNA sequencing and ex vivo functional restoration 
assays.
Results We found that CD39+ CD8 TILs were enriched 
with tumor- specific CD8 TILs, and that the activation 
status of these cells was determined by the differential 
programmed cell death protein 1 (PD-1) expression 
level. CD39+ CD8 TILs with high PD-1 expression (PD-
1high) exhibited features of highly tumor- reactive and 
terminally exhausted phenotypes. Notably, PD-1high 
CD39+ CD8 TILs showed similar characteristics in terms 
of T- cell exhaustion and activation between the primary 
and metastatic sites. Among co- stimulatory receptors, 
4- 1BB was exclusively overexpressed in CD39+ CD8 
TILs, especially on PD-1high cells, and 4- 1BB- expressing 
cells displayed immunophenotypes indicating higher 
degrees of T- cell activation and proliferation, and less 
exhaustion, compared with cells not expressing 4- 
1BB. Importantly, 4- 1BB agonistic antibodies further 
enhanced the anti- PD-1- mediated reinvigoration of 
exhausted CD8 TILs from both primary and metastatic 
sites.
Conclusion Severely exhausted PD-1high CD39+ CD8 
TILs displayed a distinctly heterogeneous exhaustion 
and activation status determined by differential 4- 1BB 
expression levels, providing rationale and evidence for 
immunotherapies targeting co- stimulatory receptor 4- 
1BB in ovarian cancers.
INTRODUCTION
Ovarian cancer has a low cure rate, and the 
fifth highest mortality rate among cancers 
in women.1 Approximately 75% of the 
newly diagnosed patients are diagnosed with 
advanced- stage disease, partly explaining 
the high mortality rate of this cancer.2 Even 
with aggressive treatment combining chemo-
therapy and debulking surgery, the 5- year 
survival rate is <30% in advanced- stage 
disease.
In the urgent quest for new treatment strate-
gies, immunotherapy has emerged as a prom-
ising new option3–5 since immune checkpoint 
inhibitors (ICIs) show remarkable success 
in several cancers.6–10 However, unlike other 
immune- reactive cancers, ovarian cancer has 
exhibited a response rate of 10%–20% to 
immunotherapy in various clinical trials using 
antiprogrammed cell death protein 1 (anti- 
PD-1), antiprogrammed death- ligand 1 and 
anticytotoxic T- lymphocyte- associated protein 
4 (anti- CTLA-4) treatments.11–14 These poor 
results highlight the need for novel immu-
notherapeutic strategies to improve the 
therapeutic efficacy of ICIs. Among various 
therapeutic strategies including combining 
ICIs with targeted agents, locoregional 
therapy and other forms of immunotherapy, 
one promising therapeutic approach is using 
agonistic antibodies to target co- stimulatory 
receptors, such as 4- 1BB, OX-40, TNFR2, 
HVEM and glucocorticoid- induced TNFR- 
related protein (GITR). Along with T- cell 
receptor (TCR) signaling, co- stimulatory 
signaling is critical for full T- cell activation 
and positively regulates T- cell differentiation, 
effector function and memory formation. 
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Therefore, agonistic antibodies targeting co- stimula-
tory receptors may be useful for augmenting anticancer 
effector functions.
Another important concern in cancer immunotherapy 
is whether an immunomodulatory drug will have the 
same effects in both metastatic sites and the primary sites. 
While it may be expected that metastatic sites will have 
similar responses to the same immunomodulatory drug, 
the effects actually differ depending on the metastasis 
site.15–17 Thus, in patients undergoing immunotherapy, 
the prognosis may depend on where metastasis occurs.18–21 
Since most patients receiving immunotherapy have meta-
static sites, determining the immune cell characteristics 
in the metastatic sites is as important as knowing the 
immune cell characteristics in the primary site. However, 
while several studies have reported differences in cancer 
cells between metastatic and primary sites,22–25 few studies 
have identified the characteristics of CD8 T cells in meta-
static sites compared with in the primary sites.
The diversity of tumor immune microenvironments 
and the different responses to immunotherapy between 
cancers26 necessitate the detailed characterization of 
tumor- infiltrating CD8 T cells in both primary and meta-
static lesions. However, studies to date are insufficient, 
particularly for ovarian cancers. Thus, in the present 
study, we aimed to investigate the immunological charac-
teristics of CD8 TILs in human ovarian cancers to identify 
distinctive activation and exhaustion statuses. We further 
examined the immunological characteristics of CD8 TILs 
in metastatic sites to evaluate how they differed from 
those in the primary sites. Finally, we investigated the 
expression of co- stimulatory receptors in CD8 TILs in the 
primary and metastatic sites to identify common effective 
targets for immunomodulatory drugs.
MATERIALS AND METHODS
Study design and patient samples
We prospectively enrolled patients who were newly diag-
nosed with pathologically confirmed ovarian cancer 
between February 2018 and February 2020 at Severance 
Hospital (Seoul, Korea). After exclusion of patients who 
underwent neoadjuvant chemotherapy, our analysis 
included 65 patients. From each patient, we collected 
whole blood samples and separately collected fresh 
tissue samples of the primary site (ovary) and metastatic 
sites when possible. Metastatic site tissues samples were 
collected from the bladder, transverse colon, spleen, 
sigmoid colon, diaphragm, cul- de- sac, peritoneum, pelvis 
and omentum. table 1 summarizes the clinical character-
istics of the enrolled patients.
From whole blood, we isolated peripheral blood mono-
nuclear cells (PBMCs) by Ficoll- Paque density gradient 
centrifugation (GE Healthcare, Uppsala, Sweden). 
To obtain single- cell suspensions of tumor- infiltrating 
lymphocytes (TILs) from tumor tissues, fresh tumor 
tissues were extracted from primary sites or metastatic 
sites and were immediately cut into small pieces (2–4 mm) 
using dissection scissors. Next, ≤1 g of tumor tissue was 
transferred to a gentle MACS C- Tube (Milteny Biotec, 
Bergisch Gladbach, Germany) containing an enzyme 
mixture (200 µL enzyme H, 100 µL enzyme R and 25 µL 
enzyme A; Milteny Biotec, Bergisch Gladbach, Germany) 
premixed with 4.7 mL RPMI. These C- tubes were then 
placed on a gentle MACS Octo Dissociator (Milteny 
Biotec) to undergo mechanical and enzymatic digestion 
using a predefined program ‘37C_h_TDK_3’ for 61 min. 
After digestion, the cell suspensions were passed through 
40 µm pore cell strainers, and then washed once. Next, 
the cells were resuspended in 10 mL media, and 20 µL of 
this suspension was stained with an equal volume of AOPI 
staining solution (Nexcelcom Bioscience, Lawrence, 
Massachusetts, USA). To determine the number and 
viability of the mononuclear cells, the stained cells were 
assessed using a Cellometer Auto 2000 (Nexcelcom). 
Finally, the cells were washed once and cryopreserved 
until further use.
Multimer staining and flow cytometry
We performed multimer staining to detect tumor- specific 
CD8 T cells and tumor- unrelated virus- specific CD8 T cells. 
To detect tumor- associated antigen (TAA)- specific CD8 T 
cells, we used two phycoerythrin- conjugated dextramers: 





  Serous 51 (78.5%)
  Mucinous 3 (4.6%)
  Endometrioid 4 (6.2%)
  Clear cell carcinoma 4 (6.2%)
  Small cell carcinoma 1 (1.5%)
  Carcinosarcoma 2 (3.1%)
Grade
  I 2 (3.1%)
  II 10 (15.4%)
  III 53 (81.5%)
Cancer stage
  I 10 (15.4%, IA: 1, IB: 0, IC: 9)
  II 5 (7.7%, IIA: 1, IIB: 4, IIC: 0)
  III 24 (36.9%, IIIA: 4, IIIB: 5, IIIC: 
15)
  IV 26 (40.0%, IVA: 4, IVB: 22)
CA 125 (U/mL) 1488.3±2313.1
HE4 (pg/L) 507.1±425.2
Data are presented as number (%) or mean±SD.
BMI, body mass index; CA 125, cancer antigen 125; HE4, human 
epididymis protein 4.
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one specific for the NY- ESO-1157–165 epitope
27 28 (SLLM-
WITQV, HLA- A*02:01), and one for the MAGE- A3112–120 
epitope29 30 (KVAELVHFL, HLA- A*02:01) (Immudex, 
Copenhagen, Denmark). To detect virus- specific CD8 T 
cells, we used two allophycocyanin- conjugated pentamers: 
one specific for the HCMVpp65495–504 epitope (NLVPM-
VATV, HLA- A*02:01) and one for the EBV LMP-2426–434 
epitope (CLGGLLTMV, HLA- A*02:01) (Proimmune, 
Oxford, UK).
For multimer staining, 1–2×106 cells were pretreated 
with 50 nmol/L of the protein kinase inhibitor dasat-
inib (Axon Medchem, Groningen, The Netherlands) for 
30 min at 37°C to inhibit TCR internalization.31 32 Then 
these cells were stained with multimers for 20 min at 4°C, 
and washed twice with fluorescence- activated cell sorting 
(FACS) buffer (phosphate- buffered saline+5% fetal 
bovine serum+1% sodium azide). Next, the cells were 
stained using the LIVE/DEAD fixable dead cell stain 
kit (Invitrogen, Carlsbad, California, USA) for 5 min at 
20°C. Cells that were not stained with multimers were 
first stained with the LIVE/DEAD fixable dead cell stain 
kit. Without washing, the LIVE/DEAD- stained cells were 
next stained with multiple fluorochrome- conjugated anti-
bodies against surface markers for 20 min at 4°C, and then 
washed again with FACS buffer. For intracellular staining, 
the cells stained with LIVE/DEAD and with antibodies 
against surface makers were fixed and permeabilized 
using a forkhead box P3 staining buffer kit (eBioscience, 
San Diego, California, USA), and then further stained 
with antibodies against intracellular proteins. Flow cytom-
etry was performed using either an LSR II instrument or 
an ARIA II cell sorter and FACSDiva software (BD Biosci-
ences, San Jose, California, USA). Data were analyzed 
using FlowJo software (Treestar, San Carlos, California, 
USA).
Multimer- positive cells were clearly identified when 
compared with fluorescence minus one controls or irrele-
vant epitope (HCV NS31406-1415)- specific multimer- stained 
cells (online supplemental figure S1A,B). Next, we strictly 
gated multimer+ cells to remove signals caused by non- 
specific binding, and confirmed that the multimer+ cells 
were tumor- specific CD8 TILs by comparing tumor- 
reactive markers (PD-1high and 4- 1BB) and the exhaustion 
status marker Tcf-1 between multimer+ and multimer– cells 
(online supplemental figure S1C). A multimer- stained 
sample was used for analysis only when ≥50 multimer+ 
cells were detected.
Online supplemental tables S1,S2 present all the anti-
bodies and FACS panels that were used in this study.
RNA sequencing
RNA sequencing (RNA- seq) was performed using sorted 
4- 1BBneg PD-1high CD39+, 4- 1BBpos PD-1high CD39+ CD8 
TILs and PD-1+CD39− CD8 TILs (reference population) 
(n=3). Cell sorting was performed in two steps: first 
with the magnetic- activated cell sorter (MACS, Miltenyi 
Biotec), and then with an ARIA II cell sorter. Total tumor- 
infiltrating cells were magnetically labeled using CD8 
microbeads, and positively selected using the MACS cell 
sorter. Next, the sorted CD8 T cells were stained with anti-
bodies against CD3, CD39, PD-1 and 4- 1BB, and sorted 
based on surface marker expressions using an ARIA II cell 
sorter (online supplemental figure S2). Online supple-
mental table S3 presents the obtained cell counts for 
each population. Finally, the sorted cells were dissolved 
in TRIzol reagent (Invitrogen). For RNA extraction, chlo-
roform was added and the samples were vigorously mixed 
by hand for 15 s and then incubated at room tempera-
ture (RT) for 2 min. Next, the incubated mixtures were 
centrifuged at 12 000 rpm for 15 min at 4°C. The aqueous 
phase was removed and mixed with 1 µL of 1:2 diluted 
glycogen (Roche 10901393001) and 1 µL isopropanol. 
These mixtures were incubated at RT for 10 min, to allow 
total RNA precipitation. Next, the samples were centri-
fuged at 12 000 rpm for 10 min at 4°C, washed with 75% 
ethanol, and then centrifuged again at 10 000 rpm for 
5 min at 4°C. The resultant RNA pellets were dried for 
10 min at RT, and then dissolved in RNase- free water. The 
purified RNA quality was measured using an Agilent 4200 
tape station. Most samples showed RNA integrity number 
(RIN) values ranging from 3.6 to 9.1, with an average of 
5.8.
RNA- seq libraries were constructed using the Ovation 
RNA- Seq System V2 kit (NuGen 7102-32). Briefly, Ovation 
RNA- Seq System V2 targets RNA through a DNA- universal 
RNA chimeric primer, and implements first and second 
complementary DNA (cDNA) synthesis. Subsequently, 
the cDNA is amplified through single primer isothermal 
amplification, with repeated hybridization and degrada-
tion of the single universal primer. To assess non- specific 
amplification, one sample was diluted 1:10 000 as a 
control for each experiment. The cDNA libraries were 
constructed using the Illumina indexed adapter attach-
ment, and converted using the MGI library conversion 
kit (MGI Tech 1000004155). The MGI libraries were 
sequenced using 100 bp paired- end mode on an MGI 
DNBSEQ- G400 sequencer.
The sequencing reads were aligned to the human 
reference genome using STAR (V.2.7.2),33 and normal-
ized for effective library size. Differentially expressed 
genes (DEGs) were analyzed using DESeq2.34 In the 
DESeq2 algorithm, first, size factors are estimated using 
the median- of- ratios method. Next, to accurately estimate 
the dispersion parameter for within- group variability, 
gene- wise dispersion estimates are generated, and are 
then shrunk toward the values predicted by the curve 
of location parameters of the distribution, to obtain 
final dispersion values. For significance testing, DESeq2 
applies a Walt test: the shrunken estimate of the loga-
rithmic fold- change divided by its SE. Finally, the Walt 
test p values are adjusted for multiple testing using the 
procedure of Benjamini and Hochberg.35 We selected 
the top DEGs based on the highest p values. To iden-
tify enriched gene ontology (GO) terms, we performed 
GO enrichment analysis with defined DEGs, and used a 
visualization tool (Gorilla tools) at http:// cbl- gorilla. cs. 
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technion. ac. il. Gene sets related to the activation and the 
exhaustion signatures of CD8 T cells36–39 were used for 
gene set enrichment analysis (GSEA) and gene set vari-
ation analysis (GSVA).40 The GEO accession number for 
our RNA- seq data is GSE160705.
The Cancer Genome Atlas data analysis
For the analysis, we obtained gene expression profiles 
and clinical data of 309 patients with ovarian cancer in 
The Cancer Genome Atlas (TCGA) database from the 
GDC Data Portal (National Cancer Institute, Rockville, 
Maryland, USA). For survival analysis, we calculated the 
gene set enrichment score via GSVA using the 177 DEGs 
(with a p value of <0.05 and log2fold- change >1) from our 
RNA- seq data. The cut- off value was determined using the 
maximal χ2 method.
Ex vivo T-cell restoration assay
The restoration capacity of tumor- infiltrating CD8 T cells 
was evaluated with regard to two aspects: function and 
proliferation. To assess the restoration capacity of tumor- 
infiltrating CD8 T cells in terms of proliferation, cryopre-
served tumor- infiltrating cells were rapidly thawed and 
labeled with CellTrace Violet (Invitrogen). Then those 
labeled cells were stimulated with 1 ng/mL anti- CD3 anti-
body (OKT-3; eBioscience), and with or without 5 µg/
mL anti- PD-1 blocking antibody (EH12.2H7; BioLegend, 
San Diego, California, USA) and 10 µg/mL anti-4- 1BB 
agonistic antibody (provided by ABL Bio, Seongnam, 
Korea). MOPC-21 (BioLegend) was used as an isotype 
control. After stimulation for 108 hours at 37°C with 5% 
CO2, the cells were harvested and stained with antibodies 
against LIVE/DEAD, CD3 and CD8. The mitotic index 
was calculated by dividing the total mitotic events by the 
number of precursor cells in each mitotic division. We 
then divided the mitotic index of the treatment group by 
that of the isotype- treated control group to determine the 
stimulation index (SI).
To evaluate the restoration capacity of tumor- infiltrating 
CD8 T cells in terms of function, we measured interferon- 
gamma (IFN-γ) and tumor necrosis factor- alpha (TNF-α) 
by intracellular staining after tumor- infiltrating cells were 
stimulated with anti- CD3 antibody and with or without 
anti- PD-1 antibody and anti-4- 1BB antibody. The cryo-
preserved tumor- infiltrating cells were thawed and then 
stimulated with 5 µg/mL anti- PD-1 blocking antibody and 
10 µg/mL anti-4- 1BB agonistic antibody in the presence 
of 1 ng/mL anti- CD3 antibody. After 24 hours of incuba-
tion at 37°C incubator with 5% CO2, we added monensin 
and brefeldin A (BD Biosciences), and the cells were 
incubated for an additional 12 hours. Finally, the cells 
were harvested and intracellular cytokines were stained 
with surface markers.
Statistical analyses
Statistical analyses were performed using Prism software 
V.8.4.3 (GraphPad, La Jolla, California, USA). We applied 
the Mann- Whitney U test and Wilcoxon matched- pairs 
signed- rank test for unpaired and paired non- parametric 
comparisons, respectively. The non- parametric Spear-
man’s rank correlation test was used to assess correlations 
between two parameters. A p value of <0.05 was consid-
ered to indicate statistical significance.
RESULTS
CD39 is predominantly expressed in tumor-specific CD8 TILs
We first analyzed the immune checkpoint receptor 
expression on CD8 TILs compared with peripheral 
blood CD8 T cells—examining PD-1, CTLA-4 and T cell 
immunoglobulin and mucin domain- containing protein 
3 (Tim-3). The frequencies of PD-1+, CTLA-4+ and 
Tim-3+ cells were significantly higher among CD8 TILs 
compared with peripheral blood CD8 T cells (figure 1A). 
Among these immune checkpoint receptors, CD8 TILs 
exhibited predominantly expression of PD-1 in terms 
of the percentage of positive cells. Recent publications 
suggest that tumor- unrelated bystander CD8 T cells are 
abundant in tumor microenvironments.41 42 Thus, we 
further examined tumor- specific CD8 TILs using two 
HLA- A*0201- restricted multimers specific to NY- ESO-1157–
165 and MAGE- A3112-120, and examined tumor- unrelated 
virus- specific CD8 T cells using multimers specific to 
HCMVpp65495–504 and EBV LMP-2426–434. Among the 
26 patients having HLA- A*0201, we detected 17 TAA- 
specific CD8 T- cell populations in 10 patients (38.5%), 
and 16 virus- specific CD8 T- cell populations in 12 patients 
(46.2%) (online supplemental table S4).
Next, we examined the expressions of PD-1, CD39, 
CD103 and CD69 as known surrogate markers for tumor- 
specific CD8 T cells42–44 (figure 1B and C). In contrast to 
prior findings, ovarian cancers exhibited no significant 
difference in PD-1 or CD69 expression between tumor- 
specific CD8 TILs and tumor- unrelated virus- specific 
CD8 TILs (ie, CMV- specific or EBV- specific) (figure 1C). 
However, the percentages of CD39+ cells and CD103+ 
cells were significantly higher among tumor- specific 
multimer+ CD8 TILs compared with among virus- specific 
CD8 TILs (figure 1C). Notably, CD39 expression was 
barely detected in virus- specific CD8 TILs (figure 1C), 
which was further confirmed by paired analysis directly 
comparing the percentage of CD39+ cells between tumor- 
specific CD8 TILs and virus- specific CD8 TILs (figure 1D). 
These results suggested that, in ovarian cancers, CD39 is 
predominantly expressed on tumor- specific CD8 TILs, 
and may thus be useful as a surrogate marker to exclude 
tumor- unrelated virus- specific bystander CD8 T cells in 
immune analysis using tumor tissues. In addition, there 
was no significant difference in the frequency of CD39+ 
cells among CD8 TILs depending on the ovarian cancer 
stages, tumor grades or tumor histology (figure 1E).
PD-1high CD39+ CD8 TILs exhibit a phenotype of terminally 
exhausted but highly tumor-reactive T cells
Based on PD-1 expression levels, we subdivided CD39+ 
CD8 TILs into three distinct populations: PD-1- negative 
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Figure 1 CD39 is predominantly expressed in tumor- specific CD8 tumor- infiltrating lymphocytes (TILs). (A) Programmed cell 
death protein 1 (PD-1), cytotoxic T- lymphocyte- associated protein 4 (CTLA-4) and Tim-3 expression on CD8 T cells, compared 
between peripheral blood mononuclear cells (PBMCs) and TILs. (B) Representative flow cytometry plots showing PD-1, CD39, 
CD103 and CD69 expression on tumor- specific multimer+ CD8 TILs and on tumor- unrelated multimer+ (virus- specific) CD8 
TILs. Gray background contour plots represent the characteristics of total CD8 TILs, and red and blue dot plots represent the 
characteristics of tumor- specific CD8 TILs and virus- specific CD8 TILs, respectively. (C) Bar graph shows cumulative data 
regarding the percentages of PD-1, CD39, CD103 and CD69 expression among total CD8 TILs (gray bars), tumor- specific 
multimer+ CD8 TILs (red bars) and tumor- unrelated virus- specific multimer+ CD8 TILs (blue bar) from the primary tumor site 
(ovary). (D) We compared eight pairs of tumor- specific multimer+ CD8 TILs and tumor- unrelated virus- specific multimer+ CD8 
TILs, which were detected in the same patients. (E) Percentage of CD39+ cells among CD8 TILs, according to cancer stage, 
tumor grade and tumor histology. Graphs show the mean and SD. **P<0.01; ***p<0.001; ****p<0.0001; ns, not significant.
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(PD-1neg), PD-1- intermediate (PD-1int) and PD-1- high 
(PD-1high) subpopulations (figure 2A). The frequency 
of PD-1high cells among CD39+ CD8 TILs did not signifi-
cantly differ according to ovarian cancer stages, tumor 
grades or tumor histology (online supplemental figure 
S3). We then examined differences in the characteristics 
of these CD39+ tumor- infiltrating CD8 T cell subpopu-
lations distinguished by differential PD-1 expression in 
ovarian cancers. The frequencies of CTLA-4+ and Tim-3+ 
cells were significantly higher in PD-1high subpopulations 
than in PD-1int or PD-1neg subpopulations (figure 2B). We 
also examined the expression of transcription factors—
such as T- bet, Eomes and Tcf-1, which contribute to the 
heterogeneous status of exhausted CD8 T cells.45–47 We 
found that PD-1high subpopulations exhibited the highest 
proportion of Eomes high expressing and T- bet low 
expressing (Eomeshigh T- betlow) cells, that is, a subset of 
terminally exhausted that is associated with poor rein-
vigoration on ICI treatment45 48 (figure 2C). On the 
other hand, the frequency of Tcf-1+ cells, which repre-
sent progenitor- like exhausted T cells associated with 
T- cell reinvigoration potential by ICIs,46 47 was lowest in 
the PD-1high subpopulation and highest in the PD-1neg 
subpopulation (figure 2D).
We next investigated parameters of tumor reactivity 
(ie, CD103) and T- cell activation (ie, CD38 and HLA- 
DR). The subpopulation of PD-1high CD39+ CD8 TILs 
exhibited the highest percentages of CD103+ cells repre-
senting tumor reactivity,43 and of CD38+ HLA- DR+ cells 
representing activation (figure 2E and F). Additionally, 
the frequency of CD38+ HLA- DR+ CD39+ CD8 TILs was 
inversely correlated with the frequency of Tcf-1+ CD39+ 
CD8 TILs (figure 2G). These findings suggested that 
PD-1high CD39+ CD8 TILs exhibit features of tumor- 
reactive but terminally exhausted T cells, indicating 
active antitumor engagement and resultant exhausted 
phenotypes.
4-1BB is predominantly expressed on PD-1high CD39+ CD8 TILs 
and features a distinctive T-cell activation status
The tumor- reactive but terminally exhausted features of 
PD-1high CD39+ CD8 TILs suggested the need for addi-
tional therapeutic strategies in combination with ICI. 
One promising approach involves targeting co- stim-
ulatory receptors.49–51 However, little is known about 
the expression patterns of co- stimulatory receptors on 
CD8 TILs, or about the immunological implications of 
co- stimulatory receptor expression in ovarian cancers. 
Therefore, we next examined the expression levels of 
various members of the tumor necrosis factor receptor 
superfamily (TNFRSF) on CD39+ CD8 TILs from 
patients with ovarian cancer, including 4- 1BB (TNFRSF9, 
CD137), CD30 (TNFRSF8), CD40 ligand (CD40L), GITR 
(TNFRSF18) and OX40 (TNFRSF4, CD134). Notably, 
compared with other TNFRSF members, 4- 1BB was more 
prominently expressed on CD8+ TILs (figure 3A). Addi-
tionally, 4- 1BB was rarely expressed on PD-1+CD39− CD8 
TILs (online supplemental figure S4).
Comparing the 4- 1BB expression levels according 
to differential PD-1 expression revealed that 4- 1BB was 
predominantly expressed on PD-1high CD39+ CD8 TILs 
(figure 3B). Indeed, terminally exhausted (PD-1high 
CD39+) CD8 TILs exhibited the highest percentage of 
4- 1BBpos cells compared with the percentages of other 
TNFRSF- expressing cells (figure 3C).
To characterize the 4- 1BBpos terminally exhausted CD8 
TILs, we further examined markers of T- cell activation 
(CD38 and HLA- DR), proliferation (Ki-67) and exhaus-
tion status (Tcf-1, Eomes and T- bet). Among PD-1high 
CD39+ CD8 TILs, compared with 4- 1BBneg cells, the 
4- 1BBpos cells displayed immunophenotypes indicating 
higher degrees of T- cell activation and proliferation, and 
less exhaustion (figure 3D).
Next, to further investigate the distinct features of 
4- 1BBpos cells among highly exhausted PD-1high CD39+ 
CD8 TILs in ovarian cancers, we performed RNA- seq 
using 4- 1BBpos and 4- 1BBneg cells sorted from PD-1high 
CD39+ CD8 TILs. We also analyzed PD-1+CD39− CD8 
TILs as a reference population (online supplemental 
figure S2). Compared with this reference population, 
the transcriptome from PD-1highCD39+ CD8 TILs was 
enriched for the genetic signature of T- cell exhaustion36 
(figure 3E). Intriguingly, compared with PD-1+ CD39− 
CD8 TILs, examination of DEGs in PD-1high CD39+ CD8 
TILs revealed that 4- 1BBpos and 4- 1BBneg cells shared 485 
DEGs in common, while an additional 683 genes were 
upregulated or downregulated in only one subpopulation 
(120 genes in 4- 1BBneg and 563 in 4- 1BBpos) (figure 3F; 
online supplemental table S5). TCF7 was differentially 
expressed between PD-1high CD39+ and PD-1+ CD39− CD8 
TILs (online supplemental figure S5A and online supple-
mental table S5). This is because the PD-1+ CD39− CD8 
TILs consist of mostly PD-1int- expressing cells (78.9%, 
online supplemental figure S5B), and this finding is 
consistent with the flow cytometry results (figure 2D).
Direct comparison of the 4- 1BBpos and 4- 1BBneg subpop-
ulations among PD-1high CD39+ CD8 TILs yielded the 
identification of 520 differentially expressed genes, of 
which 369 genes were significantly upregulated and 151 
genes were downregulated in 4- 1BBpos cells compared 
with 4- 1BBneg cells (figure 3G and H; online supple-
mental table S6). DEGs between 4- 1BBpos and 4- 1BBneg 
PD-1high CD39+ CD8 TILs were subjected to GO term anal-
ysis, revealing that 4- 1BBpos cells showed enrichment of 
genes related to ‘cell cycle process’, ‘cell division’, ‘DNA 
replication’, ‘heterocycle metabolic process’ and ‘cellular 
response to stimulus’, whereas 4- 1BBneg cells showed 
enrichment of genes related to ‘regulation of cell death’, 
‘regulation of apoptotic process’, ‘negative regulation 
of response to stimulus’, ‘negative regulation of cellular 
metabolic process’ and ‘negative regulation of immune 
effector process’ (figure 3I; online supplemental table 
S7). GSEA confirmed that, compared with 4- 1BBneg cells, 
4- 1BBpos cells exhibited significant enrichment of the 
‘activated CD8 TILs gene signature’38 (figure 3J). Addi-
tionally, GSVA analysis with the activation and exhaustion 
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Figure 2 Detailed immunological characterisation of CD39+ CD8 tumor- infiltrating lymphocytes (TILs) from the ovary according 
to programmed cell death protein 1 (PD-1) expression level. (A) CD39+ CD8 TILs were divided into three subpopulations 
based on PD-1 expression level. The left image is a representative flow cytometry contour plot, with the gray box indicating 
the subpopulation without PD-1 expression (PD-1neg), the blue box intermediate PD-1 expression (PD-1int) and the red box 
high PD-1 expression (PD-1high). The bar on the right shows the average percentages of the PD-1neg, PD-1int and PD-1high 
subpopulations among all patients. (B) Percentages of cytotoxic T- lymphocyte- associated protein 4 (CTLA-4)+ and Tim-3+ cells 
among CD39+ CD8 TILs according to the differential expression of PD-1. Contour plots on the left are representative plots. (C–F) 
Frequencies of Eomeshigh T- betlow (C), Tcf-1+ (D), CD103+ (E) and CD38+ HLA- DR+ (F) cells among subpopulations according 
to differential expression of PD-1. Left panel shows representative flow cytometry plots for each. (G) Correlation between the 
frequencies of Tcf-1+ cells and CD38+ HLA- DR+ cells among CD39+ CD8 TILs from the ovary. Graphs show the mean and SD. 
**P<0.01; ****p<0.0001.
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Figure 3 4- 1BB is predominantly expressed on programmed cell death protein 1 (PD-1)high CD39+ CD8 tumor- infiltrating 
lymphocytes (TILs) and features a distinctive T- cell activation status. (A) Compared with other co- stimulatory receptors 
belonging to tumor necrosis factor (TNF) receptor superfamily, 4- 1BB is exclusively expressed in CD39+ CD8 TILs from the 
ovary. (B) Percentages of 4- 1BB+ cells in subpopulations according to PD-1 expression. Left panel shows a representative flow 
cytometry contour plot of 4- 1BB expression according to PD-1 expression level. (C) Comparison of the expressions of various 
co- stimulatory receptors in PD-1high CD39+ CD8 TILs. (D) The frequencies of CD38+ HLA- DR+, Ki-67+, Eomeshigh T- betlow and 
Tcf-1+ cells in PD-1high CD39+ CD8 TILs, directly compared between 4- 1BBneg cells and 4- 1BBpos cells. (E–L) RNA expression 
levels PD-1high CD39+ CD8 TILs, compared between 4- 1BBneg and 4- 1BBpos cells. (E) Gene set enrichment analysis (GSEA) 
was performed to compare enrichment of the ‘T- cell exhaustion signature’ between PD-1highCD39+ CD8 TILs and PD-1+CD39− 
CD8 TILs. Normalized enrichment score (NES)=1.66, p<0.025. (F) Venn diagram shows differentially expressed genes between 
4- 1BBneg PD-1high CD39+ CD8 TILs and 4- 1BBpos PD-1high CD39+ CD8 TILs compared with PD-1+ CD39− CD8 TILs. (G) Volcano 
plots for differentially expressed genes between 4- 1BBpos PD-1high CD39+ CD8 TILs vs 4- 1BBneg PD-1high CD39+ CD8 TILs. The 
top 20 genes and 4- 1BB encoding gene, TNFRSF9, are annotated. (H) Heatmap shows differentially expressed genes between 
4- 1BBneg PD-1high CD39+ CD8 TILs and 4- 1BBpos PD-1high CD39+ CD8 TILs. In 4- 1BBpos PD-1high CD39+ CD8 TILs, 151 genes 
are downregulated and 369 genes are upregulated. Representative genes are noted. (I) The 10 significant gene ontology terms 
relatively enriched in each group. (J) GSEA revealed enrichment of the activated CD8 TIL gene signature in 4- 1BBpos PD-1high 
CD39+ CD8 TILs compared with 4- 1BBneg PD-1high CD39+ CD8 TILs (NES=1.78, p<0.0001). (K) Gene set variation analysis 
(GSVA) was performed in each group using gene signatures of ‘exhausted CD8 TILs’, ‘dysfunction module’, ‘activated CD8 
TILs’ and ‘effector CD8 T cells’. (L) The probability of 5- year overall survival in patients with ovarian cancer from the The Cancer 
Genome Atlas database according to enrichment of the ‘4- 1BB signature’ comprising 177 upregulated differentially expressed 
genes Graphs indicate the mean and SD. *P<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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signatures of CD8 T cells revealed that 4- 1BBpos cells were 
highly enriched for gene signatures related to ‘activated 
CD8 TILs gene signature’38 and ‘effector CD8 T cells 
gene signature’,37 whereas 4- 1BBneg cells were highly 
enriched for ‘exhausted CD8 TILs gene signature’38 and 
‘dysfunction module’39 (figure 3K). The 177 DEGs that 
were upregulated in 4- 1BBpos PD-1high CD39+ CD8 TILs 
compared with in the 4- 1BBneg counterpart (p value of 
<0.05 and log2fold- change >1) were defined as the ‘4- 1BB 
signature’, and tumors with high 4- 1BB signature were 
significantly correlated with better survival outcome in 
patients with ovarian cancer in TCGA cohort (figure 3L).
Overall, our results suggested that the 4- 1BBpos subpop-
ulation displays features of distinctive T- cell activation 
status, and may retain higher proliferative and reinvigo-
ration potential among highly exhausted tumor- specific 
CD8 TILs.
CD39+ CD8 TILs from metastatic sites exhibit severe T-cell 
exhaustion features similar to the primary site
Considering that most patients with ovarian cancer 
receiving immunotherapy have metastatic sites, it is 
important to understand the distinct characteristics of 
exhausted CD8 T cells from the metastatic site compared 
with the primary site. We obtained TILs from various 
metastatic sites—including the bladder, transverse colon, 
spleen, sigmoid colon, diaphragm, cul- de- sac, perito-
neum, pelvis and omentum (online supplemental table S8 
presents detailed information about the metastatic sites). 
We confirmed that CD39 is predominantly expressed on 
tumor- specific CD8 TILs also in metastatic site, wherease 
CD39 expression was barely detected in tumor- unrelated 
virus- specific CD8 TILs (figure 4A, online supplemental 
figure S6). To investigate the immunological character-
istics of CD39+ CD8 TILs in the metastatic sites, we first 
compared the expressions of immune checkpoint recep-
tors such as PD-1, CTLA-4 and Tim-3 in CD39+ CD8 TILs 
between primary sites and the metastatic sites, and found 
that the frequencies of PD-1+ and CTLA-4+ cells in CD39+ 
CD8 TILs were significantly lower in metastatic sites than 
in primary sites (figure 4B). However, there was no signif-
icant differences in the frequency of CD103+, Eomeshigh 
T- betlow cells and Tcf-1+ cells among CD39+ CD8 TILs 
(online supplemental figure S7).
For the detailed characterization of CD39+ CD8 TILs 
from metastatic sites, CD39+ CD8 TILs were subdivided by 
PD-1 expression level (figure 4C). Compared with CD39+ 
CD8 TILs from primary sites, those from metastatic sites 
exhibited a slightly lower percentage of PD-1high cells 
(41.7% vs 54.7%), and slightly higher percentage of 
PD-1int cells (40.2% vs 30.4%) (figure 4D, online supple-
mental figure S8). The frequency of PD-1neg cells did 
not significantly differ between CD39+ CD8 TILs from 
primary versus metastatic sites. These results indicated 
that although CD39+ CD8 TILs from primary and meta-
static sites showed similar frequencies of PD-1+ cells, the 
PD-1 expression level was slightly higher at primary versus 
metastatic sites. As found at primary sites, higher PD-1 
expression was associated with higher frequencies of 
CD103+, CD38+ HLA- DR+, Eomeshigh T- betlow and 4- 1BB+ 
cells, and with a lower frequency of Tcf-1+ cells (figure 4E).
We then compared features of T- cell exhaustion and 
activation between primary and metastatic sites. As shown 
in figure 4F, PD-1high CD39+ CD8 TILs from metastatic 
sites expressed similar levels of CD103, representing 
tumor reactivity; exhibited a similar frequency of CD38+ 
HLA- DR+ cells; similar frequencies of Eomeshigh T- betlow 
cells and Tcf-1+ cells and similar frequencies of 4- 1BB+ 
cells (figure 4F). These findings suggest that PD-1high 
CD39+ CD8 TILs showed similar characteristics in terms of 
T- cell exhaustion and activation between the primary and 
metastatic sites. As found at primary sites, among PD-1high 
CD39+ CD8 TILs from metastatic sites, the 4- 1BBpos cells 
displayed immunophenotypes indicating higher degrees 
of T- cell activation and proliferation, and less exhaustion, 
compared with 4- 1BBneg cells (figure 4G).
4-1BB is highly enriched in PD-1high CD39+ CD103+ CD8 TILs
We further investigated CD8 TILs from the original and 
metastatic sites to determine which subpopulation was 
most enriched with 4- 1BB+ cells. Combined t- distributed 
stochastic neighbor embedding (t- SNE) analysis of paired 
CD8 TILs from primary and metastatic sites (22 samples) 
revealed 16 different clusters, which were further grouped 
into 10 distinctive subpopulations based on differential 
expression of PD-1, CD39 and CD103 (figure 5A–B). 
Among these 10 distinct subpopulations, we found that 
the PD-1high CD39+ CD103+ subpopulation exhibited the 
highest proportion of 4- 1BB+ cells (figure 5C), as well 
as the highest proportions of CTLA-4+ cells and Tim-3+ 
cells (figure 5D). We further confirmed that the highest 
proportion of 4- 1BB+ cells was observed in PD-1high CD39+ 
CD103+ subpopulation from both primary sites and meta-
static sites (figure 5E). Analysis of PBMCs revealed that 
most CD8 T cells were PD-1int CD39– CD103– or PD-1neg 
CD39– CD103– (online supplemental figure S9).
4-1BB co-stimulation further enhances anti-PD-1-mediated 
reinvigoration of exhausted CD8 TILs
Although the PD-1high subpopulation of CD39+ CD8 TILs 
showed the features of terminally exhausted T cells, a 
significant portion expressed 4- 1BB—suggesting that 
they may retain higher proliferative and reinvigoration 
potential. Therefore, we investigated whether anti-4- 1BB 
agonistic antibodies could enhance the function of 
exhausted CD8 TILs in ovarian cancers. The ex vivo T- cell 
functional restoration assay revealed that 4- 1BB co- stim-
ulation with agonistic antibodies significantly enhanced 
CD8 TIL proliferation indicated by the SI (figure 6A), 
as CD8 TIL production of IFN-γ and TNF-α (figure 6B). 
Interestingly, anti-4- 1BB treatment also significantly 
enhanced the function of CD8 TILs from metastatic sites 
(figure 6C), suggesting that anti-4- 1BB treatment may be 
effective at both primary and metastatic sites.
Recent clinical trials of anti- PD-1 therapy in patients with 
ovarian cancer suggest that the therapeutic efficacy must 
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Figure 4 CD39+ CD8 tumor- infiltrating lymphocytes (TILs) from metastatic sites exhibit severe T- cell exhaustion features 
similar to the primary site. (A) Pairwise comparisons of CD39 expression among total CD8 TILs, tumor- specific multimer+ 
CD8 TILs and tumor- unrelated virus- specific multimer+ CD8 TILs from metastatic sites. (B) Programmed cell death protein 
1 (PD-1), cytotoxic T- lymphocyte- associated protein 4 (CTLA-4) and Tim-3 expression on CD39+ CD8 TILs, compared 
between the ovary and metastatic sites. (C) CD39+ CD8 TILs from metastatic sites were divided into PD-1neg, PD-1int and PD-
1high subpopulations according to differential expression of PD-1. On the left, a representative flow cytometry contour plot 
shows three subpopulations: gray box for PD-1neg, blue box for PD-1int and red box for PD-1high subpopulation. On the right, 
the bar shows the overall average percentages of each subpopulation among total patients. (D) Frequency of the PD-1high 
subpopulation compared between the ovary and metastatic sites. (E) Percentages of CD103+, CD38+ HLA- DR+, Eomeshigh T- 
betlow, Tcf-1+ and 4- 1BB+ cells among CD39+ CD8 TILs, compared among subpopulations. (F) Percentages of CD103+, CD38+ 
HLA- DR+, Eomeshigh T- betlow, Tcf-1+ and 4- 1BB+ cells among PD-1high CD39+ CD8 TILs from the ovary and from metastatic sites. 
(G) Percentages of CD38+ HLA- DR+, Ki-67+, Eomeshigh T- betlow and Tcf-1+ cells among PD-1high CD39+ CD8 TILs from metastatic 
sites, directly compared between 4- 1BBneg cells and 4- 1BBpos cells. Graphs indicate the mean and SD. *P<0.05; **p<0.01; 
***p<0.001; ****p<0.0001; ns, not significant.
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Figure 5 Combined t- SNE analysis of CD8 tumor- infiltrating lymphocytes (TILs) from primary and metastatic sites. (A) 
Combined t- SNE analysis was performed using 22 paired samples. Left panel, a t- SNE plot shows 16 different clusters. Right 
panel, the frequencies of each cluster. (B) Sixteen clusters were further grouped into 10 distinctive clusters based on the 
expression of programmed cell death protein 1 (PD-1), CD39 and CD103. Left panel, t- SNE plots show differential expression 
of PD-1, CD39 and CD103. Right panel, heatmap. (C) Percentages of 4- 1BB+ cells in the 10 distinctive clusters. (D) Frequencies 
of cytotoxic T- lymphocyte- associated protein 4 (CTLA-4)+ (blue bars) and Tim-3+ (green bars) cells in the 10 distinctive clusters. 
(E) Left panel, t- SNE analysis performed separately for CD8 TILs from primary and metastatic sites. Right panel, percentages of 
4- 1BB+ cells in 10 distinctive clusters analyzed separately for primary sites (red bars) and metastatic sites (blue bars). NNN; PD-
1neg CD39– CD103–, NNP; PD-1neg CD39– CD103+, NPP; PD-1neg CD39+ CD103+, INN; PD-1int CD39– CD103–, INP; PD-1int CD39– 
CD103+, IPN; PD-1int CD39+ CD103–, IPP; PD-1int CD39+ CD103+, HNP; PD-1high CD39– CD103+, HPN; PD-1high CD39+ CD103–, 
HPP; PD-1high CD39+ CD103+.
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Figure 6 4- 1BB agonistic antibodies enhanced the function of exhausted CD8 tumor- infiltrating lymphocytes (TILs). (A) 
Efficacy of 4- 1BB co- stimulation with anti- CD3 stimulation in terms of CD8 TIL proliferation. In the presence of anti- CD3 
antibodies, we analyzed the frequency of CTVlow CD8 TILs (proliferated CD8 TILs) in the presence of isotype or anti-4- 1BB 
agonistic antibodies. Representative flow cytometry plots are shown on the left, and data are presented as the stimulation 
index. (B–C) Effects of 4- 1BB co- stimulation were also assessed in terms of cytokine production, representing functional 
capacity. Interferon (IFN)-γ and tumor necrosis factor (TNF)-α production in CD8 TILs was measured by intracellular staining. 
Representative flow cytometry plots are shown on the left, and data are presented as the relative ratio to the isotype- treated 
group, separately for cells from the ovary (B) and metastatic sites (C). *P<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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be improved.14 Therefore, we lastly examined whether 
4- 1BB co- stimulation with agonistic antibodies could 
further enhance anti- PD-1- mediated T- cell reinvigoration. 
Compared with single PD-1 blockade, the combination of 
PD-1 blockade plus 4- 1BB co- stimulation with agonistic 
antibodies further enhanced the proliferative response of 
CD8 TILs (figure 7A), as well as the capacity of CD8 TILs 
to produce IFN-γ and TNF-α (figure 7B). Notably, 4- 1BB 
Figure 7 4- 1BB co- stimulation further enhances antiprogrammed cell death protein 1 (anti- PD-1)- mediated reinvigoration 
of exhausted CD8 tumor- infiltrating lymphocytes (TILs) from the ovary and metastatic sites. (A) In the presence of anti- CD3 
antibodies, we analyzed the frequency of CTVlow CD8 TILs (proliferated CD8 TILs) in the presence of isotype or anti- PD-1 
blocking antibodies, or a combination of anti- PD-1 blocking antibodies and anti-4- 1BB agonistic antibodies. Representative 
flow cytometry plots are shown to the left, and data are presented as the stimulation index. (B–C) We evaluated changes of the 
functional capacities of CD8 TILs after stimulation with antibodies by intracellular staining of cytokines (interferon (IFN)-γ and 
tumor necrosis factor (TNF)-α). We compared three different treatment groups: isotype- treated, anti- PD-1 blocking antibodies- 
treated and combined treatment with anti- PD-1 blocking antibodies and anti-4- 1BB agonistic antibodies. Representative flow 
cytometry plots are shown to the left, and data are presented as the relative ratio to the isotype- treated group, separately for the 
ovary (B) and metastatic sites (C). *P<0.05; **p<0.01; ***p<0.001; ****p<0.0001.
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co- stimulation further enhanced the anti- PD-1- mediated 
reinvigoration of exhausted CD8 TILs from both meta-
static sites and primary sites (figure 7B and C).
DISCUSSION
Although therapeutic approaches using ICIs have had 
breakthrough success in the treatment of some cancers, 
they exhibit limited efficacy in other cancer types, and 
many patients do not respond to these therapies. Over-
coming the limitations of ICIs will require a better 
understanding of T- cell exhaustion in the tumor micro-
environment (TME).
In the present study, we found that CD39+ CD8 TILs 
were enriched with tumor- specific CD8 TILs, and we exam-
ined the characteristics of subpopulations of these cells 
according to PD-1 expression level. Our results showed 
that PD-1high CD39+ CD8 TILs were highly activated and 
terminally exhausted. Among various co- stimulatory 
receptors, 4- 1BB was exclusively expressed in PD-1high 
CD39+ CD8 TILs, and these 4- 1BB- expressing cells showed 
a distinctive status of activation and exhaustion. We addi-
tionally analyzed the characteristics of CD39+ CD8 TILs 
from metastatic sites in terms of T- cell exhaustion, and 
discovered that these cells were equally highly exhausted 
like CD39+ CD8 TILs from the primary site. Additionally, 
4- 1BB expression among PD-1high CD39+ CD8 TILs was 
similar between the metastatic and primary sites. Impor-
tantly, experiments with anti-4- 1BB agonistic antibodies 
demonstrated the therapeutic potential of antibodies 
targeting 4- 1BB for reinvigoration of exhausted CD8 TILs 
at both the primary and metastatic sites.
Advanced- stage ovarian cancer has a 5- year survival 
rate of <30%, and is the fifth leading cause of female 
cancer mortality.1 The response rate of ovarian cancer to 
anti- PD-1 immunotherapy has been <20%,11–14 and only 
limited studies have examined CD8 TILs, that is, the major 
target of current immunotherapy. Several studies have 
attempted to identify new targets for immunotherapy by 
examining the surface markers of CD8 TILs; however, the 
abundance of tumor- unrelated bystander CD8 TILs in 
tumor tissues41 42 makes it difficult to conduct an efficient 
study without first identifying tumor- specific CD8 TILs.
In the present study, we first searched for a surrogate 
marker to define tumor- specific CD8 TILs in patients with 
ovarian cancer, and we found that CD39+ CD8 TILs were 
highly enriched with tumor- specific CD8 TILs. Among 
CD39+ CD8 TILs, we found that PD-1high cells represented 
tumor- reactive cells that had lost Tcf-1 expression, indi-
cating that this cell population would not be affected by 
anti- PD-1 blocking antibodies, and required additional 
treatment for restoration. TNFRSF members have been 
spotlighted as new targets for immunotherapy,49 52 53 and 
we found that 4- 1BB was prominently expressed in the 
PD-1high CD39+ CD8 TIL subpopulation. Moreover, an ex 
vivo T- cell restoration assay revealed that 4- 1BB co- stim-
ulation with agonistic antibodies further enhanced anti- 
PD-1- mediated reinvigoration of exhausted CD8 TILs 
from patients with metastatic ovarian cancers. Overall, 
these findings highlight the importance of a detailed 
characterization of the heterogeneity within the tumor- 
specific exhausted tumor- infiltrating CD8 T- cell popula-
tion in patients with ovarian cancer. Moreover, our results 
indicated that 4- 1BB co- stimulation in conjunction with 
anti- PD-1 therapy may be a potent therapeutic option.
To our knowledge, this study is the first to analyze 
distinct characteristics of tumor- specific exhausted CD8 
TILs. Several previous studies have shown genetically 
distinctive characteristics of cancer cells from metastatic 
sites compared with those from the primary tumor sites, as 
well as differences between these tumor immune micro-
environments.23 26 54 However, no prior investigation has 
included a detailed comparison of the characteristics of 
tumor- specific CD8 TILs between the primary and meta-
static sites. Some studies have focused on the differences 
in CD8 TILs between the primary and metastatic sites, but 
have only shown differences in the degree of CD8 infiltra-
tion, or in the CD8/CD3 ratio among infiltrating lympho-
cytes.55 56 Due to our insufficient knowledge regarding 
CD8 TILs at metastatic sites, current clinical or laboratory 
use of immunotherapy has been based on the assumption 
that the immunological characteristics of exhausted CD8 
TILs would be similar between the metastatic and primary 
sites—and that if there was a difference, the CD8 TILs in 
metastatic sites would be less exhausted than those in the 
primary sites. Notably, our present results suggested that 
CD39+ CD8 TILs from the metastatic sites and primary 
sites of ovarian cancer exhibited similar exhaustion status, 
although the CD39+ CD8 TILs from metastatic sites were 
slightly less activated than those from the primary sites.
Our present dataset of CD8 T cells from peripheral 
blood, primary sites and metastatic sites in cases of meta-
static ovarian cancers was the most complete reported to 
date. Therefore, we endeavored to define the phenotypic 
characteristics of tumor- reactive CD8 TILs at primary 
and metastatic sites by comparing previously reported 
surrogate markers that represent tumor- reactive T cells, 
including PD-1high,57 CD3943 and CD103.58 We found 
that at both the primary and metastatic sites, PD-1high 
CD39+ CD103+ CD8 TILs exhibited the highest propor-
tions of 4- 1BB+, CTLA-4+ and Tim-3+ cells (figure 5C), 
which have been regarded as tumor- reactive CD8 T cells 
across multiple cancer types.59–61 The PD-1high CD39+ 
CD103– subpopulation also exhibited a high proportion 
of 4- 1BB+ cells; however, we found a low frequency of the 
PD-1high CD39+ CD103– subpopulation itself among total 
CD8 TILs. Our results provide a deeper understanding 
of tumor- reactive CD8 T cells in advanced cancers with 
metastatic lesions, particularly metastatic ovarian cancers.
Our present results demonstrated that 4- 1BB co- stim-
ulation promoted the functional enhancement of CD8 
TILs from both the primary tumor sites and the meta-
static sites of patients with ovarian cancer. We performed 
a T- cell restoration assay by using anti- PD-1 blocking anti-
bodies and anti-4- 1BB agonistic antibodies to stimulate 
single- cell suspensions from ovarian cancer tissues. This 
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assay has the advantage of showing how the antibodies 
work in complex tumor microenvironments, and has 
the limitation of not revealing how individual cell popu-
lations respond to the antibodies. Previous studies have 
shown that in the tumor microenvironment, anti-4- 1BB 
agonistic antibodies can enhance the NF-κB signaling 
pathway in dendritic cells62 or reprogram tumor- induced 
regulatory T cells into cytotoxic CD4+ T cells.63 Based on 
previous findings, we can infer that the presently demon-
strated effects of 4- 1BB agonistic antibodies in reinvigo-
rating exhausted CD8 TILs were likely caused by direct 
stimulation of CD8 TILs and by the stimulation of other 
immune cells (eg, dendritic cells and regulatory T cells), 
which could result in the indirect reinvigoration of CD8 
TILs.
Our present study is the first to delineate the charac-
teristics of tumor- specific CD8 T cells from the primary 
tumor site and metastatic sites from patients with meta-
static ovarian cancer. Additional research is needed to 
further investigate the distinct characteristics of other 
immune cells, such as CD4+ T cells and regulatory T 
cells, in the TME of metastatic sites in ovarian cancers. 
Our current results provide insights that may guide the 
design of immunotherapy involving 4- 1BB co- stimula-
tion for metastatic ovarian cancers. Although concerns 
have been raised regarding hepatotoxicity of the 4- 1BB 
agonist urelumab, this problem can likely be overcome 
with urelumab dose adjustment64 or by using novel agents 
with tumor- specific properties.52 65–67
Conventional chemotherapy can modulate the compo-
sition and functionality of tumor- infiltrating immune cells 
either directly68 or indirectly by inducing the immuno-
genic cell death of tumor cells.69 Therefore, we excluded 
patients treated with neo- adjuvant chemotherapy, and 
evaluated the tumor- specific CD8 TILs of the primary 
and metastatic sites on diagnosis, given that the immune 
context at the time of diagnosis is sufficient to predict the 
prognosis and treatment outcomes.70–73 However, patients 
treated with neo- adjuvant chemotherapy are usually 
those exhibiting severe dissemination in an advanced 
stage. Therefore, one limitation of our study is that the 
exclusion of these patients may have led to an insuffi-
cient analysis of patients with advanced- stage disease or 
with potentially immunologically different microenvi-
ronments. We think that the enrollment of 26 patients 
with stage IV ovarian cancers in this study should enable 
delineation of the immunological characteristics of CD8 
TILs in patients with advanced ovarian cancer. However, 
it will be important to conduct further comprehensive 
studies to examine the changes and distinct characteris-
tics of immune cells between the primary and metastatic 
sites before and after the administration of neo- adjuvant 
chemotherapy.
In conclusion, the present results suggest that 4- 1BB 
expression among severely exhausted PD-1high CD8 TILs 
identified a further activated and less exhausted subpop-
ulation, which may represent a primary target for ICI- 
based immunotherapy. Additionally, targeting 4- 1BB 
together with anti- PD-1 blocking antibodies could be a 
promising strategy for improving the poor responses to 
immunotherapy in metastatic ovarian cancer. Future clin-
ical studies are warranted to evaluate the efficacy of 4- 1BB 
agonists in patients with ovarian cancer.
CONCLUSION
Our study suggests that severely exhausted PD-1high CD39+ 
CD8 TILs showed similar characteristics in terms of T- cell 
exhaustion and activation between the primary and meta-
static sites of ovarian cancers and PD-1high CD39+ CD8 
TILs displayed a distinctly heterogeneous exhaustion and 
activation status determined by differential 4- 1BB expres-
sion. Moreover, 4- 1BB co- stimulation further enhanced 
the anti- PD1- mediated reinvigoration of CD8 TILs. This 
study provides insights for improving the poor responses 
to immunotherapy in metastatic ovarian cancer.
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